Clover Biopharmaceuticals
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances 2025-10-20 07:00
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults 2025-10-14 18:18
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates 2025-06-17 12:48
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 2025-03-24 07:56
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY 2024-10-29 06:32
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults 2024-06-18 17:41
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort 2024-04-08 17:19
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT) 2023-12-29 07:30
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate 2023-12-13 07:42
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil 2023-11-07 08:00
1